Learn how artificial intelligence is used to design AI antibodies, marking a milestone in protein design and treatment innovation.

In this webinar, Jae Chang Lim and Hyun Joon Chang will discuss how a cutting-edge artificial intelligence platform is transforming early-stage drug discovery.

Researchers from Nobel Laureate David Baker’s lab and the University of Washington’s Institute for Protein Design (IPD) have ...

The field of oncology continues to confront the formidable challenge of addressing cancer, a leading cause of mortality ...

The rapid advancement of artificial intelligence (AI) is transforming the field of structural biology. In May 2024, DeepMind and Isomorphic Labs launched AlphaFold 3 (AF3), a revolutionary AI system ...

The integration of artificial intelligence (AI) into drug discovery is revolutionizing pharmaceutical research by providing sophisticated tools for understanding and predicting complex biological ...

Existing frameworks for explainable artificial intelligence (XAI) and AI governance, such as the EU AI Act and the NIST AI ...

Pharma companies are collaborating to boost the power of artificial intelligence (AI) in drug discovery by allowing access to proprietary structural data to train a large language model. Each of the ...

After walking away from cell therapy and narrowing its focus to just three modalities, Takeda is doubling down on its remaining strategic commitment by reupping a pact with AI drug designer Nabla Bio.